Empagliflozin (Jardiance) structure · SGLT2 inhibitor

Empagliflozin (Jardiance) 2D structure

Role: Drug
Family: SGLT2 inhibitor series
Mechanism class: SGLT2 inhibitor
Parent scaffold: C-glucoside SGLT2 pharmacophore
Indication: T2D, HFrEF/HFpEF, CKD · FDA/EMA

Structure source: Catalog seed (external identifier on file)
PubChem CID: 11949646
ChEMBL ID: CHEMBL2107830
FDA / EMA: FDA/EMA
ClinicalTrials.gov: empagliflozin heart failure
Regulatory status: Approved · FDA/EMA · ClinicalTrials.gov · ClinicalTrials.gov

How similarity is calculated

Hand-written analysis

Mechanism

엠파글리플로진은 근위세뇨관 SGLT2를 막아 포도당·나트륨 배설을 늘립니다. 혈당과 무관하게 심부전·CKD 이득이 있습니다. 생식기 감염·케톤산증 위험을 설명해야 합니다.

Medicinal chemistry

C-글루코사이드 플로리진 유도체입니다. SGLT1 잔여가 낮습니다.

Indication · context

2형 당뇨, HFrEF, CKD 등으로 적응이 확장되었습니다. 다파글리플로진과 같은 케모타입입니다.

SMILES

CCOC1=CC=C(C=C1)CC2=CC(=CC(=C2)[C@@H](C3=CC=C(C=C3)F)OCC4C(C(C(C(O4)CO)O)O)O)C5=CC=CC=C5

Related compounds

Comparisons · briefs

External IDs · BioMoa

PubChem CID 11949646 CHEMBL2107830 BioMoa · SGLT2 / Jardiance BioMoa bridge Open on the family map Flow Structure table Mechanism class

StructureMoa is a chemical-structure exploration tool. Structural similarity, clustering, and SAR relationships are intended for research exploration and do not establish shared potency, selectivity, safety, efficacy, or clinical performance.

Methodology

Empagliflozin (Jardiance) structure · mechanism